Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 56

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 56
---
 net tangible book value
per share of $0.035 to new investors (attributing no value to the Warrants and assuming the full exercise of any Pre-Funded Warrants).
We determine dilution by subtracting the as adjusted net tangible book value per share after this offering from the amount of cash that
a new investor paid for a share of common stock in this offering. The following table illustrates this per share dilution to new investors:

| Assumed combined public offering price per share of common stock and accompanying Warrants          |     |   |       |   |     | $2.455 |
|:----------------------------------------------------------------------------------------------------|:----|:--|------:|:--|:----|-------:|
| Historical net tangible book value per share as of March 31, 2025                                   |     | $ |  2.63 |   |     |        |
| Decrease in net tangible book value per share attributable to investors purchasing in this offering |     | $ | (0.21 | ) |     |        |
| As adjusted net tangible book value per share as of March 31, 2025                                  |     |   |       |   |     |  $2.42 |
| Dilution per share to investors purchasing in this offering                                         |     |   |       |   |     | $0.035 |

After completion of this offering, our existing stockholders
would own approximately 42.0% and our new investors would own approximately 58.0% of the total number of shares of our common stock outstanding
after this offering.

To the extent that outstanding options or warrants
are exercised, you will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or
strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional
capital is raised through the sale of equity or convertible debt securities, the issuance of these securities may result in further dilution
to our stockholders.

The dilution information set forth in the table above
is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

| (1) | The foregoing discussion and tables above are based on the 1,472,891 shares of common stock outstanding as of March 31, 2025, and excludes: |

| ● | 57,068 shares of common stock reserved for future issuance under the 2022 Plan